NCT05799612 2026-02-13
Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
Clinical Trials
5 trialsNCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00929019 2018-12-07
Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients
Radboud University Medical Center
Phase 1/2 Terminated
NCT02452307 2017-08-17
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
University Hospital Tuebingen
Phase 1/2 Unknown
NCT00204607 2007-04-19
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
University Hospital Tuebingen
Phase 1/2 Completed